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doi:10.1016/j.ejvs.2008.05.009Abstract Background: The maximal diameter of abdominal aortic aneurysms (AAAs) is the
dominating indication for repair. However half of the AAAs repaired would never have ruptured
if left unrepaired, although small AAAs occasionally rupture. Earlier surgery may be associated
with a lower mortality. More precise indicators for surgery are warranted. This systematic re-
view identifies potential systemic biomarkers for AAA rupture or expansion.
Methods: MEDLINE/PubMed and EMBASE (from 1985 trough May 2007) were searched with the
medical subject heading abdominal aortic aneurysm and keywords ‘‘size’’, ‘‘progression’’ or
‘‘growth’’ or ‘‘expansion rate’’ or ‘‘rupture’’ on the basis of MESH tree and as a text search
restricted to English, German, French and Italian. In addition, reference lists were studied
and manual searches performed. Observational studies investigating the association of circu-
lating biomarkers with AAA rupture, expansion or size were selected.
Data extraction: Two reviewers (SU and GU) independently extracted the following data: year
of publication, study characteristics, duration of follow-up, circulating biomarker, AAA expan-
sion rate or size or rupture.
Results: 699 papers were identified. After exclusion of thoracic aneurysms and cardiac studies
(nZ 118), surgical or medical treatment studies (nZ 179), case reports and animal studies
(nZ 87), as well as reviews or letters (nZ 66), 249 articles were selected. Also excluded were
230 papers that did not report AAA size, expansion rate or rupture. 39 papers were included.
Several potential biomarkers were identified. The strongest association with AAA was obtained
with serum elastin peptides (SEP) and plasmin-antiplasmin (PAP) complexes. Matrix-degradingvicius MD, Vascular Research Unit, Department of Vascular Surgery, Viborg Hospital, Denmark.
s@sygehusviborg.dk (S. Urbonavicius).
ty for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
274 S. Urbonavicius et al.metalloproteinase 9 (MMP9) and interferon-gamma (IFN-gamma) could have clinical potential
while many putative biomarkers showed poor association.
Conclusions: Several circulating agents in peripheral blood may predict AAA size, expansion
rate or rupture. Few of them have clinical potential for future use. Confirmative studies and
development of multivariate models are needed, together with continuing search for new bio-
markers using the discovery based sciences within proteomics and/or genomics.
ª 2008 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.Introduction
Abdominal aortic aneurysm (AAA) is an important health
problem. In cross-sectional population studies of older
men the prevalence varies from 3% to 8%. AAA causes about
1% deaths in developed countries. In elderly men AAA may
cause as many as 2% of all deaths.1 The incidence of asymp-
tomatic and ruptured AAA has increased in several coun-
tries during the last few decades.
Efforts to limit the mortality rate from AAA rupture
depend on early detection and elective AAA repair. The
indication for elective repair is mainly based upon the
maximal diameter of AAA above 5.5 cm.1,2 Consequently,
the benefit of early diagnosis of AAAs by ultrasound screen-
ing is limited because most AAAs are too small for interven-
tion at the time of diagnosis. Currently there is no
established medical treatment for small AAAs, but small
AAAs do rupture occasionally. If we could predict which
small AAAs are most likely to require later intervention, in-
tervention could perhaps be offered earlier with less mor-
bidity and mortality because age is one of the major risk
factors, and fatal ruptures during surveillance could be lim-
ited.3 However, two large randomized trials have shown
a strategy of early AAA repair to be inefficient.1,4 In addi-
tion, only half of those large AAA we operate upon would
have ruptured if they were left untreated. Consequently,
an improved risk model is desirable, to which circulating
biomarkers may contribute information.
A biomarker can be defined as a measurable cell,
protein, peptide, gene, or metabolic product that repre-
sents biologic processes in an organism at a given time.5
One or several biomarkers might be an indicator for the dis-
ease or the risk that the disease will progress. The diameter
of the AAA is a surrogate marker of the growth rate, which
reflects the magnitude of the degenerative process of the
wall, and thus becomes a surrogate marker of rupture.
The risk of rupture increases when growth exceeds the ex-
pected expansion rate.6 Active investigations continue to
identify markers other than size that would predict a risk
of rupture.7 Circulating biomarkers could also indicate opti-
mal intervals between the surveillance intervals. Finally,
the identification of biomarkers also may identify potential
pathogeneic pathways, and thus may open possibilities for
pharmacological inhibition of growth, and provide a tool
for monitoring this inhibition.
Systematic literature search
The MEDLINE/PubMed and EMBASE databases were
searched for publications with the medical subject heading
‘‘abdominal aortic aneurysms’’ and keywords ‘‘size’’, ‘‘pro-
gression’’ or ‘‘growth’’ or ‘‘expansion rate’’ or ‘‘rupture’’.The search was conducted both on basis of the MESH tree
and as a text search. We restricted our search to four
languages (English, German, French and Italian) and to the
period 1985 to May 2007. We excluded earlier studies,
because ultrasound and CT technologies were not available
before 1985. We focused only on human studies that
reported aneurysm size, expansion rates (using linear
regression modelling) and/or rupture.
Results
A total of 699 abstracts available in English were identified.
After exclusion of thoracic aneurysms and cardiac studies
(nZ 118), surgical, endovascular or medical treatment
studies (nZ 179), case reports and animal studies
(nZ 87), as well as reviews or letters (nZ 66), 249 ab-
stracts were selected. Of these we also excluded 169 pa-
pers that only investigated AAA wall material and 41
papers that analyzed AAA but did not analyze differences
in size, expansion rate or rupture. 39 papers were included,
using the biomarkers listed in Table 1.
Matrix changes: elastin and collagen
Elastin
Elastin is one of the major components of the aorta, and
experimental findings suggest that degradation products,
elastin peptides, also stimulate leukocyte recruitment and
cytokine production.8
Lindholt et al.9 invited 4404 men to screening in 1994 in
order to detect AAA. 112 patients with small AAA were of-
fered annual follow-up. Blood samples were obtained in
83 patients and serum elastin peptide (SEP) levels were de-
termined using an Enzyme-Linked ImmunoSorbent Assay
(ELISA)-technique with polyclonal antibodies against elastin
peptides. A clear, but modest, correlation between SEP and
the (expansion) growth rate within the first year of observa-
tion was identified in this prospective study (rZ 0.4).
These findings suggested that SEP could be used as a bio-
marker predicting AAA expansion.
Alan Scott10 in Chichester (United Kingdom) followed 35
patients unfit for surgery, of whom 12 ruptured later. To-
gether with Lindholt, they found that the SEP was signifi-
cantly higher in those patients whose AAA ruptured later.
ROC analysis showed that SEP could predict a later rupture
with en optimal sensitivity and specificity of 67% and 60%,
respectively. By combining SEP and last measured AAA-
size in a linear model with rupture as the dependent vari-
able, the ROC analysis showed an optimal sensitivity and
specificity of 83% and 66%, respectively. The finding was
statistically significant; however, the study was underpow-
ered due to the small sample size.
Table 1 Summary of published studies reporting the role of circulating biomarkers in the growth and rupture of AAA
Biomarker Number of
patients in
the study
Relation between
biomarkers and
AAA expansion
Summary of findings Author, year
SEP 83 rZ 0.4 Serum-elastin-peptides seem
to predict expansion, but a larger,
longer study is needed to establish
clinical recommendations.
Lindholt J.
et al., 1997
PIIINP
SEP
99
rZ 0.24; (0.02e0.44)
rZ 0.31; (0.11e0.49)
A predictive model using EP,
PIIINP, and initial AAA size
seems capable of predicting
nine out of 10 AAAs that will
be operated on within 5 years.
Lindholt J.
et al., 2001
SEDP 60
rZ 0.809, p< 0.001
rZ 0.034, pZ 0.825
There was a significantly positive
correlation between S-EDP and
diameter in patients with rAAA,
but not in patients with aAAA
(rZ 0.034, pZ 0.825)
Petersen
et al., 2001
PIIINP 139 rZ 0.55; pZ 0.002 Acceleration of AAA growth is
reflected in serum PIIINP.
Satta J.
et al., 1997
PIIINP; PICP 86 no correlation Because no correlation between
plasma and tissue levels of PIIINP
was found, the plasma level of
PIIINP cannot be used as marker
of this process.
Treska V.
et al., 2000
SEP
PIIINP
SEP
PIIINP
62
rZ 0.33; pZ 0.01
rZ 0.45; pZ 0.01
rZ 0.31; pZ 0.02
rZ 0.45; pZ 0.01
Increased elastolysis is associated
with increased AAA wall
distensibility; whereas increased
collagen turn-over is associated
with reduced distensibility.
Wilson KA
et al., 2001
MMP-9 36
rZ 0.33
rZ 0.51
Plasma MMP-9 may predict the
natural history of AAA.
Lindholt J.
et al., 2000
MMP9MMP2 76 no correlation Both MMP-2 and -9 and NIIINP
failed to show relevance as
serum markers for aortic dilatation.
Eugster T
et al., 2005
P-Elastase 79 rZ 0.30; p< 0.01 P-elastase was positively correlated with
the mean annual AAA expansion rate.
Lindholt J
et al., 2003
Cystatin C 8 rZ0.203; p< 0.03 Increased abdominal aortic diameter
correlated inversely with serum
cystatin C levels.
Shi GP
et al., 1999
Cystatin C 142
rZ0.22
rZ0.24
Deficiency of cystatin C was
associated with increased
aneurysm size and expansion rate.
Lindholt J.
et al., 2001
tPA 70 rZ 0.37; pZ 0.002 AAA progression may be partly
caused by an activation of
plasminogen by tPA
Lindholt J.
et al., 2003
PAP 70 rZ 0.39 The progression of AAA is correlated
with the PAP level
Lindholt J.
et al., 2001
IFN-gamma 50 rZ 0.37; p< 0.02 Elevated INF-gamma concentrations
seem to predict an increased rate
of expansion in AAA.
Juvonen J.
et al., 1997
TNF-alpha IL-8 90 statistically significant
correlation p< 0.05
IL-8 and TNF-alpha can be used
as endogenous markers of the
process of AAA development.
Treska V.
et al., 2000
IL-6 7 rZ 0.28; pZ 0.002 In multivariate analysis, the level
of IL-6 was independently
correlate-with indexed aortic diameter.
Rodhe LE
et al., 1999
MIF 112 rZ 0.28; pZ 0.005 A significant association between
serum MIF level and AAA initial
size and AAA expansion rate was found.
Pan JH
et al., 2003
(continued on next page)
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Table 1 (continued)
Biomarker
Number of
patients in
the study
Relation between
biomarkers and
AAA expansion
Summary of findings Author, year
Osteopontin 198 rZ 0.24; pZ 0.001 OPN may be a useful biomarker
for AAA presence and growth.
Golledge J
et al., 2007
Osteoprogerin 146 rZ 0.20; pZ 0.04 The findings support a role for
OPG in the growth of human AAA
Moran CS
et al., 2005
CRP
sympt 52
ruptured 62
no correlation A significant elevation of CRP
could be found in patients who
presented symptoms or rupture of an AAA.
Domanovits H
et al., 2002
C-reactive Protein 545 significant bivariate
interaction
CRP levels are elevated in larger
aneurysms but do not appear to be
associated with rapid expansion. The
most useful predictor of aneurysmal
expansion in men is aortic diameter.
Norman P.
et al., 2004
Fibrinogen 110 rZ 0.323; p< 0.01 Fibrinogen may be a useful marker
to monitor the progression of AAA.
Al-Barjas HS
et al., 2006
Serum highly
sensitive CRP
39 rZ 0.477; pZ 0.002 Serum hsCRP is associated with
aneurysmal size.
Vainas T.
et al., 2003
CRP 151 no correlation CRP did not correlate with size or
expansion rate of AAA.
Lindholt J
et al., 2001
S-CotinineHomocysteine 122 rZ 0.24; pZ 0.038
no correlation
S-cotinine were positively correlated
with the mean annual AAA expansion rate.
Lindholt J.
et al., 2003
D-dimer,
fibrinogen/fibrin
36
rZ 0.644; pZ 0.0001
rZ 0.561; pZ 0.0009
The largest diameter of AAA correlated
with the preoperative levels of D-dimer
and FDP. Activated state of both blood
coagulation and fibrinolysis in AAA
patients are associated with the
morphological characteristics of aneurysms.
Yamazumi K.
et al., 1998
Homocysteine 58
5.09 0.84
5.79 1.5, p< 0.05
An association between the presence of
AAA in patients selected for surgical
treatment of AAA and elevated
homocysteine plasma levels was found.
Brunelli T
et al., 2000
Homocysteine 108 rZ 0.28, pZ 0.003 HyperHCY patients have faster expansion
rates than patients with normal HCY.
Halazun KJ
et al., 2007
C. pneumoniae infection 110
IgA rZ 0.28
IgG rZ 0.45
Aneurysm progression correlated with
evidence of chronic C. pneumoniae
infection.
Lindholt J.
et al., 2001
C. pneumoniae serology 68 IgA, pZ 0.046 C. pneumoniae may contribute to aortic
aneurysm disease progression- IgA titers
positive for C. pneumoniae
Falkensammer B.
et al., 2007
Chlamydophila
pneumoniae serology
119 no correlation Study fails to demonstrate a connection
between C pneumoniae seropositivity
and AAA rupture
Nyberg A
et al., 2007
SEP- serum elastin peptides, SEDP - serum elastin derived peptides, PIIINP- aminoterminal propeptide of type III procollagen, PICP-
tissue carboxyterminal propeptide of type I procollagen, MMP-2,MMP-9- matrix-degrading metalloproteinases, tPA- tissue like plasmin-
ogen activator, PAP- plasmin- antiplasmin complexes, IFN-gamma- interferon-gamma, TNF-alpha- tumor necrosis factor-alpha, IL-6-
interleukin 6, IL-8- interleukin 8, MIF- macrophage migration inhibitory factor, CRP - C Reactive Protein, hs - highly sensitive,
C. pneumoniae - Chlamydophila pneumoniae, S e serum.
276 S. Urbonavicius et al.Petersen et al. studied serum samples from 45 consecu-
tive patients, having elective AAA repair and 15 patients
with contained AAA rupture. Patients with contained rup-
ture had significantly lower levels of SEP than patients un-
dergoing elective AAA repair. SEP was measured by
a competitive ELISA. There was a significantly positive cor-
relation between SEP and diameter in patients with con-
tained rupture (rZ 0.809, p< 0.001), but not in patients
undergoing elective AAA repair (rZ 0.034, pZ 0.825).11Later Lindholt et al.12 developed antibodies for a new
ELISA. This new ELISA showed a similar association with ex-
pansion rate but had poor correlation (rZ 0.31) with the
earlier ELISA. The authors concluded that a standardized
ELISA would be needed for clinical use.
Collagen metabolism: PIIINP
Changes in the interstitial collagens may predispose the
aneurysm to rupture. Measurement of blood procollagen
Potential Circulating Biomarkers 277peptides may serve as biomarkers of collagen turnover. In
1997, Satta et al.13 investigated the relationship between
serum amino terminal propeptide of type III procollagen
(PIIINP) and the rate of AAA expansion, and the possible pre-
dictive value of this biomarker with respect to AAA rupture.
They measured serum PIIINP in 139 patients with asymptom-
atic small AAAs who were followed-up at intervals of 6 to 12
months. AAA growth was significantly and positively associ-
ated with the concentration of PIIINP in serum (rZ 0.55).
Treska and Topolcan14 used radioimmunoassay methods
to evaluate the plasma and tissue carboxyterminal propep-
tide of type I procollagen (PICP) and PIIINP concentrations
in relation to their size and symptoms. Eighty-six patients
operated for both symptomatic AAA and asymptomatic pa-
tients with aneurysm diameter over 5 cm were examined
together with 25 patients scheduled for hernia repair or
laparoscopic cholecystectomy as a control group. The
only difference in plasma PIIINP levels was between pa-
tients with AAA and the control group. No significant asso-
ciations between PICP, PIIINP plasma levels, AAA-diameter
and symptomatology of AAA were observed.
Lindholt et al.12 showed a significant, but weak correla-
tion between PIIINP and expansion rate (rZ 0.24). In addi-
tion, they showed an independently significant association
between initial AAA size, SEP, and serum PIIINP and expan-
sion rate. The multivariate formula could, by ROC analysis,
predict cases reaching 5 cm in diameter within 5 years with
a sensitivity and specificity of 91% and 87%, respectively, in-
creasing to 91% and 94%, respectively, by accepting a 2 mm
variation in those measurements. Within the first 5 years,
23 were lost for follow-up. If all 23 are included in the anal-
ysis, the sensitivity and specificity would have been 87% and
85%, respectively.
The relationship between AAA distensibility and circu-
lating markers of elastin peptides and collagen metabolism
was examined by Wilson et al. in a cross sectional study.15
SEP, plasma elastin-a1-antitrypsin complexes (E-AT), and
PIIINP were measured in 62 male patients with asymptom-
atic small AAA with mean aorta diameter of 42 (37-45)
mm. The investigator showed that elastolysis was associ-
ated with increased AAA wall distensibility; whereas in-
creased collagen turn-over was associated with reduced
distensibility.
In 2004, Claridge et al.16 performed case-control study
within the Huntingdon Aneurysm Screening Programme.
Blood samples were taken to measure PIIINP, lipid levels,
iron metabolism and cotinine levels. The investigators did
not find any significant differences in PIIINP levels between
subjects with a small aneurysm and subjects with a normal
aorta.
Matrix modulating proteases and their inhibitors
Matrix-degrading metalloproteinases
The relationship between aortic diameter, aneurysmal ex-
pansion rate, and the expression of matrix-degrading metal-
loproteinases (MMP) has been investigated. As mentioned
earlier, Lindholt et al.17 obtained blood samples from
a cohort of men after the diagnosis of a small AAA (3e5 cm)
at population screening. Annual control scans were per-
formed to check for expansion rate of AAA. Circulating levels
of MMP-2, MMP-9, and tissue-inhibitor-metalloproteinase(TIMP) 1 and 2 were measured in a random group of 36
men. Despite the small sample size, MMP9 correlated sig-
nificantly (rZ 0.33) with expansion rate, while no other
trend was noticed.
Hovsepian et al.18 used an ELISA to determine MMP-9 in
25 patients with AAA, 15 patients with aortic occlusive dis-
ease (AOD) and 5 controls. Blood plasma MMP-9 concentra-
tions were significantly higher in patients with AAA as
compared with patients with AOD or healthy subjects. How-
ever the investigators did not observe any significant corre-
lation between blood plasma MMP-9 levels and aneurysm
size, although there was a trend toward the highest levels
in male patients with large AAAs.
In contrast, Eugster et al.19 compared serum MMP-9 and
MMP-2 in 76 men with an aortic dilatation 25 mm with ran-
domly assigned patients having normal aortic diameters.
They found no correlation between either serum MMP-2 or
-9 with AAA diameter. However, the coagulation process
during the creation of serum could easily influence the mea-
sured levels due to secretion from platelets or leukocytes.
Elastase
Obviously, elastase was one of the first proteases to be
associated with the breakdown of aortic elastin, and
smoking, one of the strongest risk factors for AAA, is known
to increase elastase secretion from leucocytes present in
the wall of the aneurysm.
Lindholt et al.20 found a significant but poor to modest
correlation with growth rate (rZ 0.30), but without any ev-
idence that elastase could predictg cases requiring surgery
latter.
Cystatin C
Cathepsins are strong candidates as key participants in
aneurysm development. These elastolytic enzymes are
expressed strongly in the AAA wall, whereas there is
reduced expression of their endogenous inhibitor cystatin
C. The possibility that circulating levels of cystatin C may
relate to the development of AAAs was explored by Shi
et al.21 This Harvard group used ELISA to measure serum
cystatin C level in 122 patients referred to an outpatient
cardiology clinic for echocardiographic testing and under-
went measurements of carotid artery intimal to medial
thickness (IMT) ratios and aortic diameter. Among these
subjects, 8 patients had an aortic diameter larger than
2.5 cm. The authors reported a significant weak negative
correlation between aortic size and cystatin C levels
(rZ0.203). The association remained significant after
adjustment for body surface area and serum creatinine (glo-
merular filtration is known to influence cystatin C levels).
In a further prospective study of 142 men with small
AAA22 followed for a mean of 2.9 years, there was a weak
negative correlation with AAA size (rZ0.22) and annual
expansion rate (rZ0.24), but no mentionable potential
for predicting cases requiring surgery later.
Plasmin, plasmin activators and the fibrinolytic system
The cysteine, serine and metallo-proteinase systems all
have been reported to be involved in the matrix degrada-
tion of the aortic wall, causing AAA. Plasmin is a common
activator and could be involved in the pathogenesis of AAA
by activating all three systems. Plasmin is formed from
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between plasminogen activators (tissue plasminogen acti-
vator (t-PA) and urokinase plasminogen activator (uPA)) and
plasminogen activator inhibitor type 1 (PAI-1). However,
when it reaches the circulation, plasmin immediately is
inactivated by antiplasmin, forming plasmin-antiplasmin
(PAP) complexes.
Lindholt et al. measured PAP in a cohort of 70 men
with small AAA and found a significant, positive but mod-
est correlation with growth rate (rZ 0.39) and a potential
of predicting cases requiring surgery within the first five
years, especially in combination with the initial AAA
size, with an optimal sensitivity and specificity both at
83%.23 They later studied the activators of plasmin in
the same cohort. Surprisingly, it was not uPA, which nor-
mally is involved in plasmin-related matrix remodeling,
but tPA that trigger this association. A significant, positive
and relatively modest correlation was found between tPA
and expansion rate (rZ 0.37).24 In a later up date of
the findings, they showed by ROC analysis that tPA was
predictive of cases expanding to above 5 cm within the
first 5 years with an optimal sensitivity and specificity of
0.73 and 0.71, respectively.25
Relationships between blood coagulation, the fibrinoly-
sis system, and the morphology of aneurysms in patients
with AAA was investigated by Yamazumi et al.26 The
authors reported that the size and tortuosity of AAA was
associated with blood levels of fibrinolytic factors such as
D-dimer, fibrinogen/fibrin degradation products, and plas-
min inhibitor-plasmin complexes. Al-Barjas et al.27 ob-
tained plasma samples from a group of 110 patients with
AAA and also demonstrated positive correlation between
the AAA size and fibrinogen concentration (rZ 0.323).
Inflammation
Cytokines and chemokines
Juvonen et al.28 measured circulating levels of interleukin 1
beta (IL-1b), interleukin 6 (IL-6), tumor necrosis factor-al-
pha (TNF-a) and interferon-gamma (IFN-g) in 50 patients
with AAA, 42 patients with coronary artery disease (CAD)
and healthy volunteers. IFN-g correlated positively and sig-
nificantly with aneurysmal expansion rate (rZ 0.37), while
no other trend was noticed.
Treska et al.29 examined 90 patients with AAA classified
according to symptoms and AAA diameter. The TNF-a and
IL-8 levels were found to be significantly low in large AAA
and in symptomatic AAAs. IL-6 levels were increased with
increasing AAA diameter and symptoms. IL-8 levels showed
a statistically significant correlation with the diameter and
TNF-a with the symptoms of AAA. Later, they analyzed
plasma endothelin 1 and 2 levels in AAA, above or below
5 cm in diameter and with or without symptoms, but with-
out any important associations being identified.30
Jones et al.31 calculated AAA growth rate from linear re-
gression analysis in 466 patients with 3 diameter measure-
ments and could not find any significant correlation with
plasma IL-6 concentration.
Macrophage migration inhibitory factor (MIF) is a well
known proinflammatory factor that influences the migra-
tion and proliferation of various cell types. Pan et al.32 fol-
lowed a cohort of 112 men with small AAAs (defined as 3 to5 cm) annually for 1 to 5 years and MIF was measured by
ELISA. The authors showed that serum-MIF levels correlated
significantly but weakly with annual expansion rate
(rZ 0.28), a correlation which persisted after adjustment
for initial AAA size, smoking habits, diastolic blood pres-
sure, ankle blood pressure index and age.
Golledge et al. used ELISA to measure serum osteopontin
(OPN).33 The regulation of OPN expression seems to play
a key role in macrophages and vascular smooth muscle cells
(SMC) migration, linked to vascular remodelling and the de-
velopment of atherosclerosis. In 198 patients with com-
plete follow-up of aortic diameter at 3 years, initial
serum OPN predicted AAA growth after adjustment for
other risk factors, however, the correlation was poor
(rZ 0.24). Osteoprotegrin (OPG) also has been evaluated
by Moran et al.34 in a cohort of 146 men with small AAA fol-
lowed up for 3 years. They observed a significant but poor
correlation between serum level of OPG and aneurysm
growth rate (rZ 0.20).
C-reactive protein
C-reactive protein (CRP) is a non-specific acute phase
reactant mainly produced in the liver stimulated by various
cytokines believed to be involved in the pathogenesis of
AAA. Thus it may be a potential biomarker. Four studies
have been reported.
A prospective cohort study35 of 545 men with small an-
eurysms were followed for a median of 48 months by Nor-
man et al. Baseline CRP levels were higher in larger
aneurysms but CRP was not associated with expansion
rate. However, the reported mean annual expansion rate
was close to half of that observed in similar cohorts in
Europe.
Lindholt et al.36 measured CRP in their cohort, but not
with the hypersensitive assay, and could not find any asso-
ciation with size or expansion rate.
Serum highly sensitive CRP (hsCRP) and the size of
aneurysm was measured in 39 patients with AAA by Vainas
et al.,37 and showed a modest correlation with aneurysm
size (rZ 0.477). Interestingly, they suggested that CRP pro-
duced in vascular tissue might contribute to aneurysm
formation.
At the same time Domanovits et al.38 compared the level
of hsCRP in 111 asymptomatic outpatients, 52 symptomatic
patients without rupture and 62 patients with rupture of
the aneurysm. Patients with symptomatic AAA and patients
with ruptured AAA had significantly elevated CRP compared
to asymptomatic patients.
Triggering factors
Hyperhomocysteinaemia
In 2000, Brunelli et al.39 reported that homocysteine (HCY)
plasma levels correlated with AAA size. However, they did
not adjust for renal function with which HCY is correlated
and tends to be impaired in aneurysmal disease, especially
among those with large AAAs. Lindholt et al. could not de-
tect any association between HCY and the growth rate of
AAA in a cohort of 70 men with small AAAs.24
However, in another recent study, Halazun et al.40 used
fluorescence polarisation immunoassays to measure fasting
total HCY levels in 108 patients undergoing surveillance for
Potential Circulating Biomarkers 279AAA. Patients with high HCY levels had faster AAA expan-
sion rates than patients with normal HCY, but the correla-
tion coefficient was weak (rZ 0.28).
Overall there are no consistent findings for HCY as
a biomarker.
Chlamydia pneumoniae and antibodies
Chlamydia pneumoniae (C. pneumoniae) has been sug-
gested to be associated with atherosclerosis. The associa-
tion between AAAs and infectious agents has also
prompted exploration of the possibility that serum antibody
titres might provide useful biomarkers of disease progres-
sion. Lindholt et al. showed that antibodies against
C. pneumoniae correlated positively with expansion rate,
not only in a Danish cohort but also in an English cohort.
They measured immunoglobulin (Ig) G and IgA titres against
C. pneumoniae by a microimmunofluorescence test. Multi-
ple linear and logistic regression analyses showed that an
IgA titre of 20 was a significant independent predictor
of increased AAA expansion.41 The same results were found
in the English cohort.42
However, antibiotic trials have been disappointing, and
the presence and role of C. pneumoniae in the AAA-wall
must be questioned. The possible link between Chlamydia
serology and AAA was later also investigated by Falkensam-
mer et al.43 in a case-control study. For 68 patients with
AAA and age-matched controls, no differences were de-
tected in the levels of IgA and IgG titres against C. pneumo-
niae. However, patients with IgA titres positive for
C. pneumoniae showed faster progressing disease (defined
as an annual increase of the aneurysm diameter of
0.5 cm) compared to patients with negative IgA titres.
Nyberg A et al.44 examined the relationship between
C pneumoniae seropositivity and AAA rupture; 119 patients
with AAA and 36 matched controls were prospectively in-
vestigated with C pneumoniae serology. Patients with rup-
tured AAA had similar levels of IgG antibodies against
C pneumoniae as patients with an electively operated
AAA, a small AAA and controls. This study failed to demon-
strate any association between C pneumoniae seropositiv-
ity and AAA rupture.
Overall there are no consistent findings relating C pneu-
moniae seropositivity to disease progression, however all 4
included studies were small.Conclusion
Several potential biomarkers for the progression of AAA
have been investigated. Most show either no correlation or
a weak correlation with the clinical course of AAA. Few
have any potential for clinical use (Table 1). SEP seems to
be one of the better biomarkers to predict expansion and
rupture, but a standardized ELISA and larger studies are
needed. PAP complexes also may have clinical potential.
MMP9 and IFN-g may warrant further evaluation.
Many of the findings are from the Viborg cohort with
substantial risk of chance findings. Another limitation
relates to the fact that many biomarkers for AAA are not
disease specific; most of them also are markers for
atherosclerosis. AAA is a multifactorial disease; some
aneurysms may have a stronger genetic component whileenvironmental factors such as smoking play a greater role in
others.
In the future, large longitudinal observational and in-
tervention studies will be necessary to assess the true
potential of matrix-turnover and other biomarkers. New
methods, including proteomics and genome wide associa-
tion studies, may identify new pathways and new potential
biomarkers.
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